Hege G Russnes

Hege G Russnes

UNVERIFIED PROFILE

Are you Hege G Russnes?   Register this Author

Register author
Hege G Russnes

Hege G Russnes

Publications by authors named "Hege G Russnes"

Are you Hege G Russnes?   Register this Author

32Publications

794Reads

6Profile Views

Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors.

Mol Oncol 2018 11 21;12(11):1838-1855. Epub 2018 Sep 21.

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Norway.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/1878-0261.12375
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12375DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210052PMC
November 2018

Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters.

Am J Pathol 2017 Oct 19;187(10):2152-2162. Epub 2017 Jul 19.

Department of Oncology, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2017.04.022DOI Listing
October 2017

Quantitative multigene FISH on breast carcinomas identifies der(1;16)(q10;p10) as an early event in luminal A tumors.

Genes Chromosomes Cancer 2015 Apr 26;54(4):235-48. Epub 2014 Dec 26.

Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, 0424, Oslo, 0310, Norway; The K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22237DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4369137PMC
April 2015

Glycan-related gene expression signatures in breast cancer subtypes; relation to survival.

Mol Oncol 2015 Apr 14;9(4):861-76. Epub 2015 Jan 14.

Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Norway; K.G. Jebsen Center for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Norway. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.12.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528768PMC
April 2015

eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN.

EMBO Mol Med 2014 Dec;6(12):1512-4

Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/emmm.201404683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287969PMC
December 2014

JARID1B is a luminal lineage-driving oncogene in breast cancer.

Cancer Cell 2014 Jun;25(6):762-77

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Broad Institute, Cambridge, MA 02141, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.04.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079039PMC
June 2014

Principles and methods of integrative genomic analyses in cancer.

Nat Rev Cancer 2014 May;14(5):299-313

1] Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway. [2] K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, 0313 Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3721DOI Listing
May 2014

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.

BMC Cancer 2014 Mar 19;14:211. Epub 2014 Mar 19.

Department of Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radium Hospital, Montebello 0310 Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-14-211DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000128PMC
March 2014

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Cell Rep 2014 Feb 23;6(3):514-27. Epub 2014 Jan 23.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA; Broad Institute, Cambridge, MA 02142, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2013.12.041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928845PMC
February 2014

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Cancer Res 2013 Nov 12;73(21):6424-34. Epub 2013 Sep 12.

Authors' Affiliations: Department of Medical Oncology and Pathology, Hospital Clínic, Institut d'Investigacions Biomediques August Pi i Sunyer, Department of Medicine, University of Barcelona; Department of Cell Biology, Immunology, and Neurosciences, Medical School, University of Barcelona, Barcelona, Spain; Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea; Department of Genetics, Oslo University Hospital Radiumhospitalet, Norway; and Department of Medicine and Experimental Oncology, Torino University, Turin, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-4573DOI Listing
November 2013

Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.

Acta Oncol 2013 Jan 30;52(1):91-101. Epub 2012 Aug 30.

Department of Oncology, Division of Surgery and Cancer Medicine, Oslo University Hospital, Radiumhospitalet, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/0284186X.2012.713508DOI Listing
January 2013

Insight into the heterogeneity of breast cancer through next-generation sequencing.

J Clin Invest 2011 Oct 3;121(10):3810-8. Epub 2011 Oct 3.

Laboratory of Molecular Pathology, Division of Pathology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI57088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195464PMC
October 2011

Paired distribution of molecular subtypes in bilateral breast carcinomas.

Cancer Genet 2011 Feb;204(2):96-102

Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cancergencyto.2010.09.012DOI Listing
February 2011

Allele-specific copy number analysis of tumors.

Proc Natl Acad Sci U S A 2010 Sep 13;107(39):16910-5. Epub 2010 Sep 13.

Department of Genetics, Institute for Cancer Research, Clinic for Cancer and Surgery, Oslo University Hospital, Montebello, N-0310 Oslo, Norway.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1186%2Fgb-2013-14-3-
Web Search
http://www.pnas.org/cgi/doi/10.1073/pnas.1009843107
Publisher Site
http://dx.doi.org/10.1073/pnas.1009843107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947907PMC
September 2010